Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | USP19 | O94966 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25701896 | 0.95 | MGLL (0.38) | MGLLALDH1A1LMNATSHRUSP2 | |
| SCHEMBL25833225 | 0.91 | MGLL (0.39) | MGLLALDH1A1LMNATSHRUSP2 | |
| SCHEMBL25927198 | 0.90 | MGLL (0.39) | MGLLS1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL23806935 | 0.90 | MGLL (0.40) | MGLLALDH1A1LMNATSHRUSP2 | |
| SCHEMBL25730280 | 0.89 | MGLL (0.39) | MGLLALDH1A1TSHRS1PR4S1PR1 | |
| SCHEMBL25479488 | 0.87 | MGLL (0.43) | MGLLALDH1A1LMNATSHRUSP2 | |
| SCHEMBL26404934 | 0.85 | MGLL (0.40) | MGLLTSHRS1PR4S1PR1S1PR3 | |
| SCHEMBL23696482 | 0.85 | MGLL (0.39) | MGLLALDH1A1LMNATSHRUSP2 | |
| SCHEMBL23696847 | 0.83 | MGLL (0.41) | MGLLALDH1A1TSHR | |
| SCHEMBL23945989 | 0.81 | MGLL (0.43) | MGLLALDH1A1TSHRS1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | MGLL 3246/4885ALDH1A1 1804/4885LMNA 2219/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MGLL 1244/4885ALDH1A1 2776/4885LMNA 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.